In vitro activity of ceftazidime, ciprofloxacin, meropenem, minocycline, tobramycin and trimethoprim/sulfamethoxazole against planktonic and sessile Burkholderia cepacia complex bacteria.

OBJECTIVES The goal of the present study was to obtain a comprehensive overview of the bacteriostatic and bactericidal effects of six commonly used antibiotics on planktonic as well as on sessile Burkholderia cepacia complex cells. METHODS The bacteriostatic and bactericidal activities of ceftazidime, ciprofloxacin, meropenem, minocycline, tobramycin and trimethoprim/sulfamethoxazole were determined against 38 B. cepacia complex strains. MICs and minimal biofilm inhibitory concentrations (MBICs) were determined using a traditional broth microdilution method and a novel resazurin-based viability staining, respectively. The bactericidal effects of the investigated antibiotics (using antibiotic concentrations corresponding to 10 x MIC; except for tobramycin, for which a final concentration of 4 x MIC was tested) on stationary phase planktonic cultures and on 24-h-old biofilms were evaluated using conventional plate count methods. RESULTS Our results confirm the innate resistance of B. cepacia complex organisms to six first-line antibiotics used to treat infected cystic fibrosis patients. All antibiotics showed similar bacteriostatic activities against exponentially growing B. cepacia complex planktonic cells and freshly adhered sessile cells (4 h). In addition, most of the antibiotics showed similar bactericidal effects on stationary phase planktonic cultures and on young and older biofilms. CONCLUSIONS Despite the general assumption that sessile cells show a decreased susceptibility to antibiotics, our data indicate similar bacteriostatic and bactericidal activity of six selected antibiotics against planktonic and sessile B. cepacia complex bacteria.

[1]  S. Aaron,et al.  A retrospective analysis of biofilm antibiotic susceptibility testing: a better predictor of clinical response in cystic fibrosis exacerbations. , 2009, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[2]  M. Dodd,et al.  Successful treatment of cepacia syndrome with combination nebulised and intravenous antibiotic therapy. , 2008, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[3]  P. Vandamme,et al.  Burkholderia latens sp. nov., Burkholderia diffusa sp. nov., Burkholderia arboris sp. nov., Burkholderia seminalis sp. nov. and Burkholderia metallica sp. nov., novel species within the Burkholderia cepacia complex. , 2008, International journal of systematic and evolutionary microbiology.

[4]  H. Nelis,et al.  Comparison of multiple methods for quantification of microbial biofilms grown in microtiter plates. , 2008, Journal of microbiological methods.

[5]  J. McElnay,et al.  Sputum antibiotic concentrations: Implications for treatment of cystic fibrosis lung infection , 2007, Pediatric pulmonology.

[6]  S. McClean,et al.  Comparison of antibiotic susceptibility of Burkholderia cepacia complex organisms when grown planktonically or as biofilm in vitro , 2007, European Journal of Clinical Microbiology & Infectious Diseases.

[7]  L. Saiman,et al.  Antimicrobial Susceptibility and Synergy Studies of Burkholderia cepacia Complex Isolated from Patients with Cystic Fibrosis , 2006, Antimicrobial Agents and Chemotherapy.

[8]  P. Bye,et al.  Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial , 2005, The Lancet.

[9]  B. Williams,et al.  Combination aerosol therapy to treat Burkholderia cepacia complex , 2005, European Respiratory Journal.

[10]  Joanna B. Goldberg,et al.  The multifarious, multireplicon Burkholderia cepacia complex , 2005, Nature Reviews Microbiology.

[11]  J. Emerson,et al.  Clinically Feasible Biofilm Susceptibility Assay for Isolates of Pseudomonas aeruginosa from Patients with Cystic Fibrosis , 2004, Journal of Clinical Microbiology.

[12]  H. Ceri,et al.  Green and red fluorescent protein vectors for use in biofilm studies of the intrinsically resistant Burkholderia cepacia complex. , 2004, Journal of microbiological methods.

[13]  Philip S. Stewart,et al.  Contributions of Antibiotic Penetration, Oxygen Limitation, and Low Metabolic Activity to Tolerance of Pseudomonas aeruginosa Biofilms to Ciprofloxacin and Tobramycin , 2003, Antimicrobial Agents and Chemotherapy.

[14]  B. Conway,et al.  Biofilm Formation and Acyl Homoserine Lactone Production in the Burkholderia cepacia Complex , 2002, Journal of bacteriology.

[15]  D. Speert.  Advances in Burkholderia cepacia complex. , 2002, Paediatric respiratory reviews.

[16]  P. Vandamme,et al.  Influence of taxonomic status on the in vitro antimicrobial susceptibility of the Burkholderia cepacia complex. , 2002, The Journal of antimicrobial chemotherapy.

[17]  P. Vandamme,et al.  Burkholderia cepacia complex infection in patients with cystic fibrosis. , 2002, Journal of medical microbiology.

[18]  W. Dunne,et al.  Bacterial Adhesion: Seen Any Good Biofilms Lately? , 2002, Clinical Microbiology Reviews.

[19]  J. Costerton,et al.  Pseudomonas aeruginosa Displays Multiple Phenotypes during Development as a Biofilm , 2002, Journal of bacteriology.

[20]  K. Lewis,et al.  Biofilms and Planktonic Cells of Pseudomonas aeruginosa Have Similar Resistance to Killing by Antimicrobials , 2001, Journal of bacteriology.

[21]  Tom Coenye,et al.  Taxonomy and Identification of the Burkholderia cepacia Complex , 2001, Journal of Clinical Microbiology.

[22]  S. Aaron,et al.  Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. , 2000, American journal of respiratory and critical care medicine.

[23]  H. Ceri,et al.  The Calgary Biofilm Device: New Technology for Rapid Determination of Antibiotic Susceptibilities of Bacterial Biofilms , 1999, Journal of Clinical Microbiology.

[24]  M. R. Brown,et al.  Increasing resistance of planktonic and biofilm cultures of Burkholderia cepacia to ciprofloxacin and ceftazidime during exponential growth. , 1998, The Journal of antimicrobial chemotherapy.

[25]  P. Vandamme,et al.  Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov. , 1997, International journal of systematic bacteriology.

[26]  M. Pepe,et al.  A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group. , 1997, Chest.

[27]  J. Costerton,et al.  Dynamic interactions of biofilms of mucoid Pseudomonas aeruginosa with tobramycin and piperacillin , 1992, Antimicrobial Agents and Chemotherapy.

[28]  J. Costerton,et al.  Enhanced activity of combination of tobramycin and piperacillin for eradication of sessile biofilm cells of Pseudomonas aeruginosa , 1990, Antimicrobial Agents and Chemotherapy.

[29]  M. R. Brown,et al.  Influence of growth rate on susceptibility to antimicrobial agents: modification of the cell envelope and batch and continuous culture studies , 1990, Antimicrobial Agents and Chemotherapy.

[30]  Adam Baldwin,et al.  Taxon K, a complex within the Burkholderia cepacia complex, comprises at least two novel species, Burkholderia contaminans sp. nov. and Burkholderia lata sp. nov. , 2009, International journal of systematic and evolutionary microbiology.

[31]  P. Vandamme,et al.  Burkholderia : molecular microbiology and genomics , 2007 .

[32]  M. Elkins,et al.  Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. , 2005, Journal of clinical microbiology.

[33]  M. Rosenfeld,et al.  Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system. , 2003, Chest.